Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27708147 | 1.00 | RAB9A (0.45) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL4328689 | 1.00 | RAB9A (0.45) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL6041432 | 0.88 | RAB9A (0.45) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL2148749 | 0.86 | TLR2 (0.41) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL5198510 | 0.86 | SLC18A3 (0.47) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL5200597 | 0.86 | SLC18A3 (0.47) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL5198776 | 0.86 | SLC18A3 (0.47) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL21291855 | 0.84 | KDM1A (0.46) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL5620724 | 0.84 | KDM1A (0.46) | RAB9ANPC1ATMSIGMAR1MAPT | |
| SCHEMBL19892791 | 0.84 | KDM1A (0.46) | RAB9ANPC1ATMSIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20060142337-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142337-A1 | Piperidine derivative and use thereof | AR, AHR, ARNT | RAB9A 1581/4885NPC1 2934/4885ATM 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.